 entered in 13 trials of CAS vs CEA and that clear
conclusions on the treatment of asymptomatic patients
were not possible.
CREST9 has been the only recent multicenter randomized trial that entered a significant number of individuals
(1181 patients) with asymptomatic carotid artery stenosis.
The published results show that although the risk of stroke
with CAS was greater than for CEA in the asymptomatic
patients, this was not statistically significant. The